



BIOCELL CHEMICALS & PHARMACEUTICALS LTD.

0784 8723017



BIOFIL CHEMICALS & PHARMACEUTICALS LTD.

Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)

Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date 30/05/2018

To,
The Secretary,
Corporate Relationship Department,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street Fort,
Mumbai 400001

To,
The Secretary,
Corporate Compliance Department,
The National Stock Exchange of India Limited
Bandra Kurla Complex, Mumbai

Sub.: Submission of declaration regarding unmodified opinion of the Auditors on
the Company for the year ended 31st March,



MAHESHWARI & GUPTA
CHARTERED ACCOUNTANTS

Auditor's Report On

Audited Financial Results of Quarter and Year Ended of 31st March, 2018
Biofil Chemicals and Pharmaceuticals Limited

11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718, 2723016-17

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31st March 2018

(Amount in Lakhs except EPS)

Statement of Audited Financial Results for the Quarter and Year ended 31st March 2018						
Particulars	3 months ended (31/03/2018)	Preceding 3 months ended (31/12/2017)	Corresponding 3 months ended in the previous year (31/03/2017)	Audited for the year ended March 31 2017	Audited for the year Ended March 31 2018	
	Audited	Reviewed	Audited	Audited	Audited	
I Revenue from Operation	355.18	91.11	625.66	1347.74	1236.00	
II Other Income	5.37	3.69	8.04	11.49	10.07	
III Total Revenue (I + II)	360.55	94.80	633.70	1359.23	1246.07	
IV Expenses						
(a) Cost of materials consumed	38.88	13.15	30.22	90.41	77.75	
(b) Purchases of stock-in-trade	278.08	14.18	330.93	762.02	991.06	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(85.80)	0.50	16.03	(1.32)	(91.70)	
(d) Employee benefits expense	31.89	18.01	25.40	53.22	72.93	
(e) Finance Cost	3.68	3.77	5.11	16.36	15.06	
(f) Depreciation and Amortisation Expense	8.30	7.11	8.85	28.42	29.63	
(g) Other expenses	66.03	15.73	65.23	179.08	92.53	
Total expenses (IV)	341.05	72.44	481.78	1128.19	1187.25	
V Profit/ (Loss) before exceptional items and tax (III-IV)	19.49	22.35	151.92	231.04	58.82	
VI Exceptional Items	0.00	0.00	1.62	0.00	0.00	
VII Profit/ (Loss) before tax (V - VI)	19.49	22.35	150.30	231.04	58.82	
VIII Tax expense:						
(1) Current tax						
(2) Deferred tax Credit/(Charge)	11.75	0.00	50.00	51.62	11.75	
IX Profit/(Loss) for the period from continuing operation (VII-VIII)	0.00	0.00	0.00	0.00	0.00	
X Profit/(Loss) for the period for dis-continued operation	7.74	22.35	100.30	179.42	47.07	
XI Tax expenses of discontinued operation	0.00	0.00	0.00	0.00	0.00	
XII Profit/(Loss) for the period for dis-continued operation after tax (X-XI)	0.00	0.00	0.00	0.00	0.00	
XIII Profit/ (Loss) for the period (IX+XII)	0.00	0.00	0.00	0.00	0.00	
XIV Other Comprehensive Income	7.74	22.35	100.30	179.42	47.07	
A) (I) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	
(II) Income Tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	
B) (i) Items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	
(II) Income Tax relating to items that will be reclassified to Profit or Loss						
c) Other Comprehensive Income (net of tax)	0.00	0.00	0.00	0.00	0.00	
XV Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	7.74	22.35	100.30	179.42	47.07	
XVI Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38	1627.38	
XVIII Earnings per equity shares (for continuing operation):						
(1) Basic (Rs)	0.05	0.14	0.62	1.10	0.29	
(2) Diluted (Rs)	0.05	0.14	0.62			



1. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (Ind As) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2016.

2. The above audited financial results of the company for the quarter and year ended March 31, 2018 were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on May 30, 2018.

3. The above Audited financial Results of the Quarter and Year ended March 31, 2018

BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.
CIN L24233MP1985PLC002709

Segmentwise Revenue, Results and Capital Employed for year ended 31st March -2018

S.No.	Segment Revenue	(Amount in Lakhs)				
		Quarter Ended			Year Ended	
		March 31 ,	December 31,	March 31 ,	31 March	31 March
		2018	2017	2017	2018	2017
1	Segment Revenue	Audited	Reviewed	Audited	Audited	Audited
	Pharma Unit	301.03	36.58	662.49	1,053.13	1,205.08
	Chemicals Division	54.14	54.53	41.23	180.02	139.08
	Plastic Division	0.00	0.00	0.28	2.84	1.28
	Other	5.37	3.69	(70.30)	10.07	13.79
	Gross Turnover	360.55	94.80	633.70	1,246.07	1,359.23
2	Segment Results					
	Pharma Unit	30.78	8.30	156.00	56.31	250.24
	Chemicals Division...	(6.55)	21.55	(29.57)	26.91	(21.46)
	Plastic Division	4.40	(3.75)	6.72	(4.01)	(7.26)
	Other	(8.41)	0.00	19.84	(8.41)	19.84
	Total Segment Profit Before Tax	20.22	26.10	152.99	70.79	243.36
	Interest Income	3.03	0.00	2.69	3.03	2.69
	Interest Expenses	3.75	3.75	3.76	15.00	15.01
	Other Unallocable Income net of Expenditure					
	Profit Before Tax	19.49	22.35	151.92	58.82	231.04
	Provision for current tax	11.30	0.00	50.00	11.30	50.00
	Item Related Earlier Year	0.45	0.00	1.62	0.45	1.62
	Profit After Tax	7.74	22.35	100.30	47.07	179.42
3	Capital Employed					
	Segment Assets (A)					
	Pharma Division	1,485.86	1,417.27	1,309.64	1,485.86	1,309.64
	Chemicals Division	866.71	854.12	802.50	866.71	802.50
	Plastic Division	62.89	67.88	71.90	62.89	71.90
	Other					
	Total (A)	2,415.46	2,339.26	2,184.04	2,415.46	2,184.04
	Segment Liabilities (B)					
	Pharma Division	898.26	874.91	703.01	898.26	703.01
	Chemicals Division	41.52	40.47	66.53	41.52	66.53
	Plastic Division	158.96	152.24	144.85	158.96	144.85
	Other					
	Total (B)	1,098.74	1,067.61	914.38	1,098.74	914.38
	Total Capital Employed (Segment Assets-Segment Liabilities)					
	Pharma Division	587.60	542.36	606.63	587.60	606.63
	Chemicals Division	825.19	813.65	735.97	825.19	735.97
	Plastic Division	(96.07)	(84.36)	(72.95)	(96.07)	(72.95)
	Other	0.00	0.00	0.00	0.00	0.00
	Total Capital Employed (Segment Assets-Segment Liabilities)	1,316.73	1,271.65	1,269.65	1,316.73	1,269.65

DATE : 30/05/2018
PLACE : INDORE

BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.
INDORE
RAMESH SHAIK
MANAGING DIRECTOR
DIN: 00028819

BIOFIL CHEMICALS and PHARMACEUTICALS Ltd.
AUDITED FINANCIAL STATEMENT OF ASSETS AND LIABILITIES AS AT 31-03-2018
CIN L24233MP1985PLC002709

		(Rs. In Lacs)	
Particulars	As at 31/03/2018	As at 31/03/2017	
A ASSETS			
1 Non-current assets:			
(a) Property, Plant & Equipment	924.684	916.453	
(b) Capital work in Progress			
(c) Other Intangible Assets			
(d) Financial Assets:			
i. Investments			
ii. Trade Receivables			
iii. Loans			
(e) Other Non- Current Assets			
Sub-total - Non-current assets	924.684		